Last reviewed · How we verify

NiQuitinTM Nicotine Lozenge

McNeil AB · Phase 1 active Small molecule

NiQuitinTM Nicotine Lozenge is a Small molecule drug developed by McNeil AB. It is currently in Phase 1 development. Also known as: NiQuitinTM lozenge.

At a glance

Generic nameNiQuitinTM Nicotine Lozenge
Also known asNiQuitinTM lozenge
SponsorMcNeil AB
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NiQuitinTM Nicotine Lozenge

What is NiQuitinTM Nicotine Lozenge?

NiQuitinTM Nicotine Lozenge is a Small molecule drug developed by McNeil AB.

Who makes NiQuitinTM Nicotine Lozenge?

NiQuitinTM Nicotine Lozenge is developed by McNeil AB (see full McNeil AB pipeline at /company/mcneil-ab).

Is NiQuitinTM Nicotine Lozenge also known as anything else?

NiQuitinTM Nicotine Lozenge is also known as NiQuitinTM lozenge.

What development phase is NiQuitinTM Nicotine Lozenge in?

NiQuitinTM Nicotine Lozenge is in Phase 1.

Related